Clinical trial for Status Epilepticus
Official title Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
ClinicalTrials.gov ID: NCT04421846
What this study is testing
- What it's testing
- The study aims to learn how these severe epilepsy conditions work by examining the collected samples.
- Who it's for
- It looks for patients who have status epilepticus or epilepsy linked to dysimmune encephalitis, as well as control patients.
- What's involved
- Participants give blood and spinal fluid samples, and some may provide tissue samples after death. No treatment is given.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 and older
You may be able to join if
- Patients aged 2 years or above, with status epilepticus.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
You likely can't join if
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty.
See the full eligibility criteria
- Patients aged 2 years or above, with status epilepticus.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty.
- Patients with status epilepticus.
- Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.
The study team makes the final eligibility decision.
Where it is enrolling
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Paris, France. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.